Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18 F-FDG PET/CT in Renal Cell Carcinoma.
Clin Nucl Med
; 49(10): e523-e524, 2024 Oct 01.
Article
em En
| MEDLINE
| ID: mdl-39192514
ABSTRACT
ABSTRACT Targeted immunotherapy became the most advanced approach for cancer treatment. Programmed death-1 (PD-1) expressed on activated T cells can reverse immune suppression and cause T-cell activation. Nivolumab, a PD-1 immune checkpoint inhibitor antibody that is a fully human immunoglobulin G4, blocks PD-1 and promotes antitumor immunity. Cabozantinib (tyrosine kinase inhibitor) inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors 1, 2, and 3. As a result of enhancing immune response in normal tissues, immune-related adverse events can occur. Thyroid dysfunction is a common form of immune-related adverse event and seen on 18 F-FDG PET/CT scans post therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Carcinoma de Células Renais
/
Fluordesoxiglucose F18
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Nivolumabe
/
Imunoterapia
/
Neoplasias Renais
/
Anilidas
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Nucl Med
Ano de publicação:
2024
Tipo de documento:
Article